GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewoong Pharmaceutical Co Ltd (XKRX:069620) » Definitions » EV-to-FCF

Daewoong Pharmaceutical Co (XKRX:069620) EV-to-FCF : -12.17 (As of Apr. 23, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Daewoong Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daewoong Pharmaceutical Co's Enterprise Value is ₩2,159,911 Mil. Daewoong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-177,511 Mil. Therefore, Daewoong Pharmaceutical Co's EV-to-FCF for today is -12.17.

The historical rank and industry rank for Daewoong Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

XKRX:069620' s EV-to-FCF Range Over the Past 10 Years
Min: -7756.35   Med: -13.65   Max: 6299.33
Current: -12.27

During the past 13 years, the highest EV-to-FCF of Daewoong Pharmaceutical Co was 6299.33. The lowest was -7756.35. And the median was -13.65.

XKRX:069620's EV-to-FCF is ranked worse than
100% of 546 companies
in the Drug Manufacturers industry
Industry Median: 23.27 vs XKRX:069620: -12.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-23), Daewoong Pharmaceutical Co's stock price is ₩129900.00. Daewoong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩2150.000. Therefore, Daewoong Pharmaceutical Co's PE Ratio (TTM) for today is 60.42.


Daewoong Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Daewoong Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewoong Pharmaceutical Co EV-to-FCF Chart

Daewoong Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.01 -58.58 447.17 -88.90 -11.94

Daewoong Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.90 -34.91 -13.40 -12.36 -11.94

Competitive Comparison of Daewoong Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Daewoong Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daewoong Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daewoong Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Daewoong Pharmaceutical Co's EV-to-FCF falls into.


;
;

Daewoong Pharmaceutical Co EV-to-FCF Calculation

Daewoong Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2159911.049/-177510.604
=-12.17

Daewoong Pharmaceutical Co's current Enterprise Value is ₩2,159,911 Mil.
Daewoong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-177,511 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daewoong Pharmaceutical Co  (XKRX:069620) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Daewoong Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=129900.00/2150.000
=60.42

Daewoong Pharmaceutical Co's share price for today is ₩129900.00.
Daewoong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2150.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Daewoong Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Daewoong Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Daewoong Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
12, Bongeunsa-ro 114-gil, Daewoong Pharmaceutical Building, Gangnam-gu, Seoul, KOR
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Daewoong Pharmaceutical Co Headlines

No Headlines